Vinblastine
Information
- Drug Name
- Vinblastine
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A combination of metronomic vinblastine therapy an... | KDR | KDR UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| The sensitivity of melanoma cell lines to daunomyc... | ABCC1 | ABCC1 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| The results indicate that although Muc4(+) cells e... | MUC4 | MUC4 EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03233347 | Active, not recruiting | Phase 2 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | October 13, 2017 | July 8, 2025 |
| NCT03159897 | Active, not recruiting | Phase 3 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | August 1, 2017 | May 2024 |
| NCT03004833 | Active, not recruiting | Phase 2 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | February 21, 2017 | December 2023 |
| NCT03646123 | Active, not recruiting | Phase 2 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | January 28, 2019 | June 7, 2026 |
| NCT03712202 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | November 28, 2018 | September 23, 2024 |
| NCT02979522 | Active, not recruiting | Phase 1/Phase 2 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | September 6, 2017 | September 24, 2029 |
| NCT03517137 | Active, not recruiting | Phase 2 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | August 1, 2019 | November 16, 2026 |
| NCT03585465 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | March 26, 2019 | January 2028 |
| NCT03407144 | Active, not recruiting | Phase 2 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | April 9, 2018 | February 13, 2027 |
| NCT02840409 | Active, not recruiting | Phase 2 | Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) | August 1, 2016 | August 2026 |
| NCT02710734 | Active, not recruiting | Phase 2 | Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) | February 24, 2016 | February 2034 |
| NCT03331341 | Active, not recruiting | Phase 2 | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | January 9, 2019 | July 1, 2029 |
| NCT01771107 | Active, not recruiting | Phase 1/Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | March 7, 2013 | February 28, 2025 |
| NCT05008224 | Active, not recruiting | Phase 2 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | October 7, 2021 | May 22, 2024 |
| NCT01712490 | Active, not recruiting | Phase 3 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | November 9, 2012 | January 13, 2026 |
| NCT00504504 | Completed | Phase 2 | Rituximab and ABVD for Hodgkin's Patients | March 2001 | March 2012 |
| NCT00003027 | Completed | Phase 3 | Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma | November 13, 1997 | |
| NCT00003084 | Completed | Phase 2 | Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer | December 1997 | November 2002 |
| NCT00520403 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer. | September 2007 | March 2010 |
| NCT00001570 | Completed | Phase 1 | A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer | February 1997 | January 2001 |
| NCT00654732 | Completed | Phase 2 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | March 19, 2008 | September 5, 2018 |
| NCT00808639 | Completed | Phase 2 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | December 2008 | September 2016 |
| NCT01056679 | Completed | Phase 1 | Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients | April 2010 | February 2016 |
| NCT01060904 | Completed | Phase 1 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | January 2010 | September 2012 |
| NCT01134861 | Completed | Phase 3 | Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer | July 1994 | March 2012 |
| NCT01148446 | Completed | Phase 3 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | January 2003 | |
| NCT01251107 | Completed | Phase 3 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | March 2000 | November 2009 |
| NCT00003376 | Completed | Phase 3 | Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | December 3, 1998 | |
| NCT00003389 | Completed | Phase 3 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | June 17, 1999 | May 2016 |
| NCT01700946 | Completed | Phase 2 | Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | April 15, 2013 | July 24, 2021 |
| NCT00369681 | Completed | Phase 2 | Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | May 2006 | October 2014 |
| NCT00002561 | Completed | Phase 3 | Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease | January 25, 1994 | January 6, 2012 |
| NCT00006237 | Completed | Phase 3 | S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma | August 2000 | July 2012 |
| NCT00002715 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma | April 1989 | October 2015 |
| NCT00030264 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas | February 2001 | March 2016 |
| NCT00038558 | Completed | Phase 3 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | November 2001 | March 2005 |
| NCT00002855 | Completed | Phase 3 | Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer | August 1996 | June 2005 |
| NCT00086801 | Completed | Phase 2 | Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma | May 2004 | May 2011 |
| NCT00147875 | Completed | Phase 1/Phase 2 | Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma | March 2004 | |
| NCT00215046 | Completed | Phase 2 | Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis | March 2000 | October 2006 |
| NCT00002882 | Completed | Phase 3 | Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma | November 1995 | April 2006 |
| NCT00264953 | Completed | Phase 3 | HD11 for Intermediate Stages | May 1998 | |
| NCT00265018 | Completed | Phase 3 | HD10 for Early Stages | May 1998 | |
| NCT00352027 | Completed | Phase 2 | Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma | July 20, 2006 | November 15, 2022 |
| NCT00498979 | Completed | Phase 1 | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | May 2007 | January 2012 |
| NCT01884922 | Completed | Phase 1 | Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults | May 29, 2013 | April 28, 2016 |
| NCT00002495 | Completed | Phase 3 | SWOG-9133 RT w/ or w/o Doxorubicin and Vinblastine in Stage I or Stage II Hodgkin's Disease | September 1992 | April 2014 |
| NCT02177695 | Completed | Phase 2 | S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer | August 28, 2014 | December 1, 2022 |
| NCT02181738 | Completed | Phase 2 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | August 12, 2014 | December 27, 2022 |
| NCT02292979 | Completed | Phase 2 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. | March 2015 | June 2, 2022 |
| NCT02343718 | Completed | Phase 1 | Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours | June 24, 2015 | January 16, 2019 |
| NCT02412670 | Completed | Phase 2 | Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer | August 27, 2015 | May 10, 2022 |
| NCT02414568 | Completed | Phase 2 | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin | July 17, 2015 | November 10, 2020 |
| NCT06204614 | Not yet recruiting | Early Phase 1 | Drug Screening Using IMD in Bladder Cancer | February 14, 2024 | July 1, 2025 |
| NCT03755804 | Recruiting | Phase 2 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | December 12, 2018 | July 1, 2028 |
| NCT06377566 | Recruiting | Phase 2 | A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | April 17, 2024 | April 2027 |
| NCT06164275 | Recruiting | Phase 2 | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | February 6, 2024 | December 31, 2031 |
| NCT05404945 | Recruiting | Phase 2 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | July 26, 2022 | October 3, 2027 |
| NCT05180825 | Recruiting | Phase 2 | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy | May 5, 2022 | December 1, 2031 |
| NCT03033914 | Recruiting | Phase 1/Phase 2 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | January 25, 2017 | January 2026 |
| NCT05137262 | Recruiting | Phase 2 | A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | October 13, 2021 | August 31, 2026 |
| NCT02205762 | Recruiting | Phase 2/Phase 3 | LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis | November 2, 2016 | July 2025 |
| NCT05062278 | Recruiting | Phase 2 | Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis | July 26, 2021 | December 1, 2025 |
| NCT04638790 | Recruiting | Phase 3 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) | February 1, 2020 | December 31, 2026 |
| NCT04685616 | Recruiting | Phase 3 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | April 14, 2022 | September 2032 |
| NCT00635726 | Terminated | Phase 2 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | February 2008 | February 2013 |
| NCT00005047 | Terminated | Phase 3 | 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer | August 1997 | December 2014 |
| NCT00005090 | Terminated | Phase 3 | S9901 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Men With Stage III or Stage IV Hodgkin's Disease | April 2000 | May 2005 |
| NCT00024167 | Terminated | Phase 3 | Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | April 2002 | |
| NCT00072215 | Terminated | Phase 3 | Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors | April 2004 | April 2005 |
| NCT00225173 | Terminated | Phase 2 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | October 2001 | September 2006 |
| NCT00512980 | Terminated | Phase 2 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | August 2008 | |
| NCT00516750 | Terminated | Phase 2 | Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin | July 2007 | February 2009 |
| NCT01390584 | Terminated | Phase 2 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | May 24, 2013 | May 18, 2018 |
| NCT01542255 | Terminated | Phase 2 | Metronomic Therapy in Patients With Metastatic Melanoma | June 2010 | January 2013 |
| NCT01887522 | Terminated | Phase 2 | Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults | July 6, 2016 | April 25, 2021 |
| NCT03912818 | Terminated | Phase 2 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | April 10, 2019 | August 11, 2022 |
| NCT03527628 | Unknown status | Phase 2 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | January 1, 2018 | January 15, 2022 |
| NCT01476410 | Unknown status | Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | November 2011 | May 2021 |
| NCT01468740 | Unknown status | Phase 2 | Prospective Study on HIV-related Hodgkin Lymphoma | March 2004 | July 2012 |
| NCT01639521 | Withdrawn | Phase 2 | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer | May 2013 | May 2013 |